Telomerase is the enzyme responsible for maintaining and lengthening telomeres — and it is normally suppressed in adult somatic cells. HBOT's fluctuating oxygen environment — breathing 100% O₂ at elevated pressure, then returning to normal — may create a hormetic stress signal that activates telomerase expression in immune cells. This hormetic mechanism is consistent with how other beneficial stressors (exercise, intermittent fasting) are known to activate repair and maintenance pathways that are normally dormant. The 38% telomere lengthening documented in the Hachmo study is consistent with a meaningful telomerase activation response.

Senescent cells — cells that have stopped dividing but resist programmed death — accumulate progressively with age and drive chronic low-grade inflammation through a secretory phenotype known as SASP (senescence-associated secretory phenotype). The 37% reduction in senescent cells documented in the Hachmo study suggests HBOT may enhance the body's ability to identify and clear senescent cells — a process called "senolysis." Whether this occurs through improved immune surveillance, direct cellular apoptosis signaling, or indirect effects of reduced inflammatory burden is an active area of research.

The intermittent hyperoxia-hypoxia cycle created by HBOT sessions — followed by return to normal oxygen levels — is being studied as a form of mitochondrial hormesis. Mitochondria respond to controlled oxygen stress by upregulating their own repair mechanisms, increasing biogenesis (creation of new mitochondria), and improving efficiency. Declining mitochondrial function is one of the central hallmarks of cellular aging — and HBOT's hormetic oxygen cycling may represent one of the cleanest non-pharmacological ways to stimulate mitochondrial renewal in aging cells.

Research at the University of Pennsylvania documented an 800% increase in circulating stem cells following HBOT — cells that migrate to sites of tissue damage and support repair. In the context of cellular aging, this stem cell mobilization may represent enhanced tissue maintenance capacity: more circulating repair cells available to replace aged or senescent cells in multiple tissue types. If HBOT both reduces the senescent cell burden and simultaneously increases the availability of replacement cells, the combined effect on tissue quality and function could be meaningfully greater than either effect alone.

Senescent cells drive chronic low-grade inflammation through SASP — secreting pro-inflammatory cytokines, chemokines, and matrix metalloproteinases that damage surrounding tissue and accelerate aging in neighboring cells. This "inflammaging" is increasingly recognized as a central driver of age-related disease across nearly every organ system. By reducing senescent cell burden by 37%, HBOT may substantially reduce the inflammatory burden these cells generate — creating a less inflammatory tissue environment that is more conducive to healthy cellular function and longevity.

Hypoxia-inducible factor 1-alpha (HIF-1α) is activated by HBOT's oxygen cycling and sits at the intersection of oxygen sensing, cellular metabolism, and longevity signaling. HIF-1α influences multiple pathways associated with longevity research, including AMPK activation, autophagy (cellular self-cleaning), and mitophagy (clearance of damaged mitochondria). These downstream effects of HIF-1α activation may contribute to the cellular rejuvenation effects documented in the Hachmo study — adding molecular pathways beyond telomerase and senolysis to the picture of how HBOT influences cellular aging biology.